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Abstract
Small molecules have played an important role in delineating molecular pathways involved in embryonic development and
disease pathology. The need for novel small molecule modulators of biological processes has driven a number of targeted
screens on large diverse libraries. However, due to the specific focus of such screens, the majority of the bioactive potential
of these libraries remains unharnessed. In order to identify a higher proportion of compounds with interesting biological
activities, we screened a diverse synthetic library for compounds that perturb the development of any of the multiple
organs in zebrafish embryos. We identified small molecules that affect the development of a variety of structures such as
heart, vasculature, brain, and body-axis. We utilized the previously known role of retinoic acid in anterior-posterior (A–P)
patterning to identify the target of DTAB, a compound that caused A–P axis shortening in the zebrafish embryo. We show
that DTAB is a retinoid with selective activity towards retinoic acid receptors c and b. Thus, conducting zebrafish
developmental screens using small molecules will not only enable the identification of compounds with diverse biological
activities in a large chemical library but may also facilitate the identification of the target pathways of these biologically
active molecules.
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Introduction
Small molecules have proved to be powerful tools for
understanding the importance of molecular pathways in develop-
ment and disease. When compared to traditional genetic
mutations, they have the advantage that they can be used to
reversibly perturb the functions of molecules at different points of
embryonic development or disease progression. Due to the
concentration-dependent effects of small molecules on their
targets, it is also possible to uncover phenotypes that result from
partial inactivation of a pathway. Their intracellular permeability
permits their use in cultured cells as well as whole organisms and
makes them candidates for use in therapeutics. This has made the
identification of novel small molecule modulators of important
genetic networks an area of intense interest.
In an effort to discover novel disease modulators, a number of
synthetic and natural chemical libraries have been assembled in
recent years [1–3]. The relative simplicity of purified proteins,
cultured cells, and other in vitro systems has been utilized
successfully in many targeted small molecule screens, resulting in
the identification of novel biological tools and therapeutic
candidates [4,5]. However, such screens interrogate a library for
very specific interactions with one or a few protein targets, and
hence only the small percentage of the library with one specific
activity is uncovered. Thus, to explore the full potential of a
diverse chemical library, a vast number of targeted screens would
be essential. In contrast, the use of a complex but sensitive assay
capable of identifying perturbations in thousands of potential
targets simultaneously affords the possibility of uncovering a large
proportion of all unknown modulators of biological pathways
contained in these libraries. Zebrafish embryos make an ideal
model system for in vivo small molecule screens due to their small
size, optical transparency, accessibility during development ex utero,
and permeability to small molecules [6]. Moreover, since
embryonic development and patterning require the precise
regulation of myriad different genetic networks, they are extremely
sensitive to perturbations by small molecule modulators.
A majorchallengeofemploying phenotypicscreens foridentifying
small molecules is delineating their molecular targets. Zebrafish
embryogenesis progresses through a strictly stereotypical sequenceof
events choreographed by numerous signaling pathways. Perturba-
tion of these molecular pathways leads to distinct and predictable
defects in the embryos that are easily detectable and have been
extensively characterized for thousands of genetic mutants (www.
zfin.org). Therefore, in many cases, the developmental defects
caused by a small molecule can be linked with high resolution to a
specific genetic pathway known to cause the same defect.
Many biological pathways that govern embryonic development
remain active in the adult, and the study of embryonic
development has led to important insights into the role of these
pathways in adult physiology and perturbations that lead to
disease. Therefore, small molecule modulators of gene networks
active in early development can lead to a better understanding of,
and design of therapeutics for, adult diseases.
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focused on a specific biological process but rather have searched
broadly for all mutations causing visible phenotypes of any kind.
These screens have identified phenotypes ranging from subtle
morphological defects of the ear to cardiac arrhythmias.
Subsequently, positional cloning has linked many of these
phenotypes to specific gene mutations. In a similar way, zebrafish
small molecule screens can interrogate a small molecule library
broadly for all compounds causing visible phenotypes of any kind,
and comparison to known mutant phenotypes can link specific
small molecules with genes that cause similar phenotypes. We
screened a small molecule library for compounds that affect
patterning and organ development in zebrafish embryos. We have
identified more than 100 compounds that perturb a number of
different aspects of development, including body-axis, brain, heart,
and vascular development. In this report, we examine one of these
compounds, DTAB, as an illustration of how zebrafish phenotypes
can connect small molecules with their molecular targets. DTAB
was identified for its ability to cause an anterior-posterior (A–P)
axis-patterning defect in the embryos. Guided by the known role
of retinoic acid (RA) in A–P patterning in embryos we were able to
show that DTAB exhibits a retinoid-like activity and is able to
phenocopy the effects of RA treatment on zebrafish embryos.
Using receptor activity assays, we demonstrate that DTAB is also
able to activate the retinoic acid receptors (RARs and RXRs) with
selectivity for RAR-c.
Results
Developmental screen for small molecule modulators
of development
To identify small molecule modulators of development, 5760
compounds from a diverse synthetic chemical library (Chembridge
Corporation, Diverse set E) were screened. Embryos at 1–4 hours
post fertilization (hpf) were treated with the compounds and scored
for obvious developmental defects in the body-axis, brain, heart,
blood and vasculature at 24, 48 and 72 hours. 5540 compounds
out of the 5760 tested (96%) caused no discernible phenotype at
72hpf and 45 compounds (0.8%) resulted in toxicity leading to
death. 175 (3%) compounds affected normal development of the
zebrafish embryos. Of these, 61 caused general developmental
delay or embryos failed to hatch out of the chorion and 8
compounds caused severe disruption of multiple structures during
development. The remaining 106 compounds caused phenotypes
that included effects on the brain (21), heart morphology and
function (43), blood and vasculature (28), gut (3), trunk and tail
(20), pigment formation (3), and touch responsiveness (3) (Fig. 1A).
The small molecule DTAB (IUPAC: 3-[(4,6-diphenoxy-1,3,5-
triazin-2-yl)amino]benzoic acid) (Fig. 2A), caused a shortening of
the body axis.
Figure 1. Zebrafish small-molecule screen identifies compounds that effect development. a) 4% of the 5760 compounds screened
affected zebrafish embryos. 19% of the active compounds caused lethality. 175 compounds with detectable effects on zebrafish development were
identified. b–c) The small molecules used for screening had molecular weights ranging from approx. 200 daltons to 700 daltons and had log P
(partition coefficient) values ranging from 210 to +15. However, the log P of the bioactive compounds were restricted to 0 to +12. b) log P values
between octanol and water of all the compounds screened plotted against their molecular weights. c) log P values of all the bioactive compounds
(excluding the toxic compounds) plotted against their molecular weights.
doi:10.1371/journal.pone.0001947.g001
Figure 2. DTAB causes anterior-posterior axis defects. a)
Chemical structure of DTAB. b) Embryos treated with higher
concentrations of DTAB showed more anterior-posterior patterning
defects than those treated with lower concentrations. Zebrafish
embryos were treated from 1hpf to 48hpf with different concentrations
of DTAB. c) Embryos treated earlier in development, and thus for longer
duration were more severely affected than those treated later. Embryos
were exposed to 3 mM DTAB from different times of development to
48hpf and compared to embryos treated with the vehicle DMSO.
Vehicle (DMSO) treated controls developed normally. All observations
were made at 48hpf.
doi:10.1371/journal.pone.0001947.g002
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Since 96% of the compounds in the library did not appear to
have any effect on embryogenesis we compared the chemical
properties of the active and inactive compounds to identify
properties that might determine biological activity. The ability of a
compound to produce a phenotype in embryos depends on its
physico-chemical properties as well as its interaction with
developmentally relevant molecules. In terms of their size
distribution the active compounds exhibited no bias and included
the full size-range of the library, from 200 daltons (Da) to 700 Da
(Fig. 1B–C). The partition coefficient between octanol and water
(logP) of the total library screened ranged from 210 to +15, thus
containing both hydrophilic and hydrophobic compounds
(Fig. 1B). However, the logP of the active compounds clustered
between 0 and +15 with a marked absence of hydrophilic
compounds. Within the hydrophobic range, there appeared to be
no bias (Fig. 1C). Thus we speculate that hydrophilic compounds,
as measured by a negative log P value are rarely active in
embryonic zebrafish screens, perhaps because they penetrate
zebrafish embryos less effectively.
DTAB causes a shortening of anterior-posterior axis
Treatment of embryos with DTAB (12.5 mM) at 1hpf caused a
severe patterning defect resulting in embryos with almost no
identifiable morphological features except scattered melanocytes
across the skin surface (Fig. 2B). At 3 mM the head and tail
structures were still reduced but a number of somite boundaries
were apparent. At 1.5 mM there was evidence of head structures
with brain folds and poorly developed eyes. There was no blood
circulation and embryos exhibited pericardial edema. At the
lowest concentration tested (0.75 mM) the A–P axis was extended
to nearly normal lengths and anatomical structures appeared
normal. Blood circulation was also normal.
In order to determine if the molecular target of DTAB was
functional early or late in development, the embryos were exposed
to 3 mM DTAB at different developmental stages from 1hpf to
24hpf (Fig. 2C). DTAB appeared to affect development at all
stages, but embryos exposed later in development exhibited
weaker phenotypes, indicating a cumulative effect over time.
Severity of the phenotype was also a function of the length of
exposure. Embryos exposed for longer time periods showed more
severe phenotypes compared to those incubated in the compound
for shorter time intervals followed by removal of the compound
from the water (data not shown).
In situ hybridization for early developmental markers was
performed in order to elucidate the molecular nature of the short-
axis phenotype. Dorso-ventral patterning defects result in short
anterior or posterior structures [7]. So, we analyzed the expression
of krox20, a marker for dorsally derived hindbrain segments
rhombomere 3 and 5. Krox20 expression was completely absent in
embryos treated with 12.5 mM of DTAB at 4hpf onwards (Fig. 3
A–B). MyoD expression indicated that myoblasts were correctly
specified in the emerging somites, however there was a severe
reduction in the total number of somites compared to untreated
embryos further confirming the general shortening of the anterior-
posterior (A–P) axis in the embryos (Fig. 3C–D). Staining for
pax2.1 in ventral structures such as pronephric ducts and dorsal
structures like the midbrain-hindbrain boundary, optic stalk and
otic vesicle were also absent, with only residual staining in the
spinal chord neurons (Fig. 3E–F). Thus, DTAB was able to ablate
both dorsal as well as ventral structures. No tail (ntl) and goosecoid
(gsc) are expressed in overlapping domains in the dorsal region of
the shield stage embryos. As gastrulation progresses, the two
domains separate with gsc moving anteriorly and ntl moving
posteriorly [8]. In situ hybridization revealed that expression of ntl
as well as gsc was reduced upon exposure to DTAB, thus indicating
there is a reduction in both the anterior and posterior derived
structures (Fig. 3G–J).
Figure 3. DTAB affects the expression of early developmental
markers. In situ hybridizations of zebrafish embryos show that
treatment with DTAB results in severe reduction of krox20, pax2a,
myoD, ntl, gsc,a n draldh2 staining. DTAB treated embryos exhibited an
upregulation of cyp26a1 transcripts in the tail and head. Embryos were
treated with 12.5 mM DTAB or DMSO control from 4hpf onwards until
fixation. Embryos were fixed at 75% epiboly (G–L), 10-somite (M–N),
18-somite (C–F) and 26-somite (A,B) stages. A–B, E–F, M–N are lateral
views with anterior to the left and dorsal to the top. C–D are dorsal
views with anterior to the left. G–L are dorsal views with the animal
pole to the top.
doi:10.1371/journal.pone.0001947.g003
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The retinoic acid signaling pathway is known to play an
important role in the anterior-posterior patterning of heart, brain,
limbs, and somitic mesoderm [9] [10] [11] [12]. Since DTAB
treated embryos exhibit defects in patterning consistent with a
short A-P axis we assessed if RA-signaling is perturbed by DTAB.
Retinoic acid is synthesized in the body by the action of Raldh2
(Retinaldehyde dehydrogenase2). Raldh2 is under the negative
feedback regulation of RA. Further regulation of RA levels in the
tissue is carried out by Cyp26s, RA metabolizing enzymes of the
cytochrome P450 family that are induced by an increase in
endogenous RA levels [13]. We analyzed the expression of raldh2
by in situ hybridization and found that during gastrulation (80%
epiboly) it is expressed in the dorsal side of the embryo in the
region flanking the presumptive notochord (Fig. 3K–L). Treat-
ment with DTAB caused a decrease in the raldh2 transcript levels
but the expression domains were maintained. Next we analyzed
the expression of cyp26a1 in zebrafish embryos. In the absence of
any treatment, 6–8 somite stage embryos express high levels of
cyp26a1 in the tail bud. DTAB treated embryos exhibited an
increase in the tail bud expression as well as in the anterior region
of the developing brain (Fig. 3M–N). Taken together, these results
suggest that there is an increase in RA signaling in DTAB treated
embryos.
In order to understand the role of DTAB in RA signaling, we
compared embryos treated with DTAB, all trans-RA, and DEAB, a
small molecule inhibitor of Raldh2 activity. Embryos treated with
DTAB or RA exhibited remarkably similar patterning defects
leading to severely shortened anterior-posterior axis (Fig. 4A).
DEAB treated embryos had a distinctive phenotype of smaller
heads, curved body axis and pericardial edema. When ntl
expression of DTAB and RA treated embryos were compared,
they exhibited a similar loss of expression in the dorsal half of the
margin. DEAB treated embryos showed no change in the ntl
expression pattern. Expression of cyp26a1 was significantly
upregulated in the RA, as well as DTAB treated embryos when
compared to vehicle treatment. DEAB treatment caused an almost
complete loss of cyp26a1 expression, which is consistent with its
induction by RA signaling. In summary, DTAB and RA elicit
similar responses in zebrafish embryos.
An increase in RA signaling, such as occurs in giraffe [14], a
zebrafish mutant in the gene cyp26a1, causes an increase in the
distance between the krox20 (rhombomeres 3 and 5) and the myoD
(somites) staining domains while the Raldh2 mutant neckless [15]
Figure 4. DTAB mimics effects of RA on early development. a) Treatment with DTAB, RA and DTAB+DEAB results in anterior-posterior
shortened phenotype. DEAB alone caused pericardial edema, twisted body axis and downregulation of cyp26a1. DEAB treatment did not affect the
ntl staining while RA and DTAB treatment led to a loss of ntl staining in the dorsal margin. DTAB, RA and DTAB+DEAB caused an increase in cyp26a1
staining but DEAB alone caused downregulation of cyp26a1. Embryos were treated with DTAB (12.5 mM), RA (1 mM), DEAB (10 mM) and DTAB+DEAB
or DMSO from 1hpf to 48hpf (for the bright field photography) and to 70% epiboly (for in situ hybridization for ntl and cyp26a1). Live bright field
embryos are shown anterior to the left and dorsal to the top. In situ hybridized embryos, are shown, dorsal view with the animal pole to the top. b)
DTAB and RA treatment caused an expansion in the distance between the krox20 and myoD positive domains. DEAB caused a compression of the
‘neck’ region and led to a decrease in the distance between krox20 and myoD domains. Embryos treated with DMSO, DTAB (1.6 mM), RA (0.125 mM)
and DEAB (10 mM) were fixed at 9-somite stage and hybridized for krox20 (rhombomeres 3 & 5) and myoD (somites). Following in situ hybridization
the embryos were de-yolked and flattened under a coverslip for better visualization.
doi:10.1371/journal.pone.0001947.g004
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somites [14]. We compared the effects of RA (0.125 mM), DTAB
(1.6 mM) and DEAB (10 mM) treatments on the distances between
krox20 and myoD domains in embryos. Consistent with previous
reports, treatment with RA increased the distance between krox20
and myoD markers when compared to vehicle treated embryos
(Fig. 4B) while DEAB treatment reduced the distance significantly.
DTAB treatment of embryos caused an increase in the distance
between krox20 and myoD staining, thus confirming that DTAB
mimics RA in zebrafish embryos.
In order to understand if DTAB elicited its effects by stimulating
endogenous RA synthesis, we treated embryos with both DTAB
and DEAB. Co-treated embryos resembled embryos treated with
DTAB alone (Fig. 4A). Expression of ntl and cyp26a1 further
confirmed that DTAB is able to induce RA signaling in embryos in
the absence of Raldh2 function, thus indicating that DTAB
activates RA signaling directly.
DTAB activates RAR and RXR receptors
Retinoic acid is a lipophilic molecule that traverses the plasma
membrane and binds to nuclear hormone receptors to activate
target gene transcription [16]. There are two families of RA
receptors known as RARs (Retinoic acid receptors) and RXRs
(Rexinoid receptors) that transduce RA signals to activate
transcription [17]. Differential expression and affinity of the
RARs and RXRs for RA and its metabolites determine the
different roles they play during development and disease [18] [19].
Since DTAB mimics effects of RA on gene expression and
embryo morphology we tested DTAB for RA receptor activation.
We compared the ability of RA and DTAB to activate RAR and
RXR receptors in a luciferase reporter based assay in Hek293T
cells. As previously reported RA was found to be a potent activator
of RARs and RXRs (Fig. 5). DTAB also activated a number of
RARs and RXRs, but exhibited strongest activity toward RARc,
with significant activity toward RARb. DTAB caused a very
modest activation of RARa, RXRa, and RXRc, and no
significant activation of RXRb at concentrations tested. Thus,
we conclude that DTAB is a retinoid that exhibits differential
selectivity for RARc over all the other receptors tested.
Discussion
Forward genetic screens in flies, worms, and zebrafish have
provided useful insights into the processes of patterning and
embryonic development. It has become increasingly evident that
the same pathways that are involved in early development are also
employed in controlling adult physiology, and that misregulation
of these pathways leads to disease. Thus, small molecule
modulators of genetic networks involved in early development
can be instrumental in understanding and designing therapeutics
for adult diseases. This connection between developmental defects
and discovery of novel therapies is well demonstrated by the use of
cyclopamine, a hedgehog signaling antagonist, in prostate [20],
gastric [21], and breast cancer [22] therapies. Cyclopamine was
serendipitously discovered as a plant compound that caused
cyclopia in the progeny of sheep that grazed on the plants [23].
We have previously employed the same reasoning in identifying
dorsomorphin, a novel small molecule inhibitor of BMP signaling,
that caused dorsalization in zebrafish embryos and shows promise
in developing therapeutics for anemia of chronic disease [24].
In order to uncover the richness of biological activities within
existing chemical libraries, we performed a broad, phenotype-based
screen on zebrafish embryos and identified numerous small
molecules that perturbed a wide variety of different processes during
development. We also observed that all the bioactive compounds
identified in this screen clustered into a group with higher
hydrophobicity when compared to the uniform distribution of
hydrophilic and hydrophobic compounds in the whole library. We
speculate that the increased hydrophobicity of compounds increases
their permeability in zebrafish and that designing libraries enriched
for compounds with log P values .0 could increase the ‘hit-rates’ of
such libraries in zebrafish assays. However, it is worth noting that
using zebrafish-based screens exclusively for small molecule
discovery would preclude the identification of hydrophilic com-
pounds with potentially interesting biological activities.
Our broad, high-content screen identified compounds affecting
development of heart, blood, vasculature, brain, and body-axis.
However, identifying target pathways of small molecules that
cause complex phenotypes is often a challenge. To illustrate the
strength of zebrafish in target identification, we selected DTAB,
which causes anterior-posterior patterning defects in embryos, as a
test case. As the retinoic acid pathway is known to be involved in
A–P patterning, we deduced and were able to confirm that DTAB
indeed functions as a retinoid. Thus, we demonstrate that the use
of previously characterized mutant phenotypes and known roles of
pathways in zebrafish embryogenesis can expedite the identifica-
tion of molecular targets of small molecules.
Retinoic acid, a product of Vitamin A (retinol) metabolism, is a
very important regulator of development and differentiation. In the
vertebrate embryo, RA plays a crucial role in a variety of processes
such as patterning of the anterior-posterior axis [25] and
development of organs including heart [26], brain [10], and limb
[11]. RA and its metabolites also play a crucial role in adult
physiological functions such as promoting growth and differentia-
tion,regulating apoptosis, andmaintaining homeostasisin numerous
tissues [27]. These pleiotropic roles of RA have been successfully
harnessed for treatment of dermatological diseases as well as cancer
therapy [27] [28]. RA is the first successful targeted drug for cancer
and is still used to treat acute promyelocytic leukemia (APL) [27].
However, the success of RA treatment is limited by the rapidity with
which RA is degraded in the body [29] and the pleiotropic effects of
RA on the organism that lead to non-specific toxicity and retinoic
acid syndrome [30]. Hence, discovery of retinoids with resistance to
metabolism and/or restricted activity on different receptors, is an
area of intense interest [29,31,32].
Interestingly, we found that DTAB exhibits selective activity
towards RARc and to a lesser extent towards RARb, compared to
the broad activity of RA. RARc is predominantly expressed in the
skin in the adult organism [19]. However, a number of other
retinoid receptors are also expressed in the skin, the most
abundant being RARt. Psoriasis, a skin disease has been
successfully treated with Tazarotene, a retinoid with selective
activity towards RARb and RARc [32] [33], indicating a specific
role for RARc and/or RARb in the disease. DTAB, with its
selective activation of RARb and RARc could potentially be used
to develop alternative therapies for this condition.
Decreased RARc activity has been implicated in ovarian
cancer, and AHPN (CD437), an RARc agonist, has been shown to
induce apoptosis and inhibit growth of ovarian tumor cell lines as
well as transplanted tumors in nude mice [34,35]. RARc is also
expressed in primitive hematopoietic stem cells (HSC). Recent
studies show that mice null for RARc have reduced numbers of
HSCs and that activation of RARc ex vivo can induce HSC self-
renewal [36]. RARc null mice also exhibit a non-HSC-
autonomous myeloproliferative syndrome (MPS) [37]. Thus,
RARc selective agonists may be useful in understanding and
designing therapeutics for multiple diseases characterized by
reduced activity of RARc.
In Vivo Retinoid Discovery
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Zebrafish maintenance
For all experiments TUAB zebrafish lines were used. Fish
embryos were incubated in non-buffered E3.
Small molecule screening
Zebrafish embryos at ,1hpf were arrayed in round-bottomed
96-well plates in 100 ml of E3. Each 384-well plate of Chembridge
diverse set E compounds (in DMSO) was transferred to four 96-
well plates. The compounds from the 96-well plates were pin-
Figure 5. DTAB selectively activates RARb and RARc receptors. RA showed high efficiency in activating the RAR and RXR receptors. DTAB was
a potent activator of RARb and RARc, but showed reduced efficiency towards RARa and RXRs. Hek293T cells were transfected with a luciferase
reporter plasmid, a b-gal transfection-control plasmid and an RA receptor plasmid, as indicated. Cells were treated with 10
29 Mt o1 0
25 M
concentrations of DTAB or RA at 24 hours after transfection and harvested at 48 hours post transfection for luciferase and b-gal reporter assays. RA
treated cells are shown by solid green squares and line and DTAB treated cells by solid blue triangles and line. Control cells transfected with only the
luciferase and b-gal reporter plasmids (with no RA receptor plasmid) and treated with various concentrations of RA are shown by dashed gray line
and gray circles. All luciferase readings were normalized to b-gal transfection controls. b-gal readings remained approximately equal throughout each
experimental set showing equal transfection efficiency and cell viability. X-axis denotes RA or DTAB concentration. Y-axis represents arbitrary
luminescence values. All RA and DTAB activities were normalized to the respective no-treatment controls. The maximum activity was set to 100% and
all values calculated thereof.
doi:10.1371/journal.pone.0001947.g005
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Embryos were incubated with the compounds in a humidified box
at 28uC and were screened for phenotypes at 24hpf, 48hpf and
72hpf under a dissecting microscope. Compounds of interest were
re-tested in 24-well plates.
Partition coefficient analysis
Log P values of the whole tested library were calculated from
values provided by Chembridge.
Chemical compounds
All-trans-retinoic acid (RA) and 4-Diethylaminobenzaldehyde
DEAB) were purchased from Sigma. Stock solutions of RA
(1 mM) and DEAB (10 mM) were prepared in DMSO. DTAB
(5133623) was purchased from Chembridge Corporation and a
12.5 mM stock was made in DMSO.
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed essentially as
previously described [38] using probes krox20 and myoD [15],
cyp26a1 and raldh2 [39], goosecoid (gsc) and no tail (ntl) [8] and pax2a
[40]. For each experiment with different treatments of com-
pounds, hybridization was carried out in parallel and color
development was allowed to run for the same amount of time for
all samples. Digoxigenin-labelled RNA antisense probes were
generated with Promega RNA transcription reagents.
Receptor activity assays
Hek293T cells were grown in DMEM containing 10% de-
lipidated fetal calf serum for 24 hours and were transfected with
either [pCMX-Gal-L-hRAR (with Gal4 DNA binding domain-
RAR Ligand binding domain)+tk-px3-luc+tk-bgal] or [pCMX-
mRXR+tk-apoA1-luc+tk-bgal]. ‘No-receptor’ controls were trans-
fected with [tk-luc+tk-bgal] and treated with various concentra-
tions of RA. 24 hours after transfection the cells were treated with
RA, DTAB or left untreated. Cell lysates collected at 48 hours
post-transfection were assayed for luciferase activity using the
Promega luciferase reporter kit. The assay results were corrected
against b-gal activity assayed using Promega b-gal reporter kit. All
the reported results are from assays done in triplicates and
repeated at least once. All the plasmids were kind gifts from
Ronald M. Evans [41] or derived from those plasmids by cDNA
subcloning.
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